Macugen

Treatment for Macular Degeneration

FDA Announces Advisory Committee Meeting Date for Macugen (pegaptanib sodium injection)

NEW YORK, May 26, 2004 -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye, has learned today that the Food and Drug Administration has announced the forthcoming meeting of a public advisory committee of the FDA to discuss the new drug application 21-756, pegaptanib sodium injection (proposed trade name, Macugen) by Eyetech Pharmaceuticals, Inc., indicated for the treatment of exudative (wet) age-related macular degeneration to be held on August 27, 2004 at 8:00 AM EDT at FDA in Rockville, Maryland.

About Eyetech Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. The company's most advanced product candidate is Macugen (pegaptanib sodium injection), which Eyetech is developing with Pfizer Inc for the prevention and treatment of diseases of the eye and related conditions. Eyetech's lead clinical trials include two phase 2/3 pivotal clinical trials for the use of Macugen in the treatment of the wet form of age-related macular degeneration and a phase 2 clinical trial for the use of Macugen for the treatment of diabetic macular edema.

For further information, please visit www.eyetech.com

SOURCE Eyetech Pharmaceuticals, Inc.

Posted: May 2004

Related Articles

Macugen (pegaptanib) FDA Approval History

View comments

Hide
(web3)